Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

Gene expression profiles of the nephron by urine mRNA: A liquid biopsy to investigate molecular changes in sickle cell nephropathy

Ajit Venkatakrishnan, Maria Armila Ruiz, Lupe Salas et al. Nov 03, 2025 pp. 529-529 10.1182/blood-2025-529

Abstract Introduction: Sickle cell disease (SCD) is associated with damage to all of the segments of the kidney's nephron, including the glo...

Machine learning-based cost prediction in pediatric allogeneic bone marrow transplantation: Development and validation of an interactive clinical decision support tool

Mayada Abu Shanap, Rawad Rihani, Duaa Zandaki et al. Nov 03, 2025 pp. 6213-6213 10.1182/blood-2025-6213

Abstract Background: Allogeneic bone marrow transplantation (BMT) costs exhibit substantial variability, yet robust prediction models for he...

DNMT3A, NPM1, and FLT3-ITD triple-mutated AML has a favorable prognosis in the era of FLT3 inhibitors

Shirley Mo, Alex Ambinder, Amy DeZern et al. Nov 03, 2025 pp. 1710-1710 10.1182/blood-2025-1710

Abstract Background: FLT3-ITD mutations are common in AML, occur in a diverse co-mutation landscape, and are generally associated with a poo...

Etentamig plus pomalidomide-dexamethasone combination therapy in relapsed or refractory multiple myeloma: A phase 1b dose-escalation and safety expansion study

Peter Voorhees, Anita D'Souza, Hang Quach et al. Nov 03, 2025 pp. 247-247 10.1182/blood-2025-247

Abstract Introduction: Etentamig is a differentiated, 2nd generation, B-cell maturation antigen (BCMA) x CD3 bispecific T-cell engager compo...

Preclinical development of an optimized manufacturing, CRISPR-edited, fully non-viral 1XX-enhanced anti-BCMA CAR-T therapy for multiple myeloma

Alexis Talbot, Ke Li, Jae Hyun Jenny Lee et al. Nov 03, 2025 pp. 5958-5958 10.1182/blood-2025-5958

Abstract Background: B-cell maturation antigen (BCMA)-targeted chimeric antigen receptor T cell (CAR-T) therapies have transformed treatment...

Modified-release formulation of decitabine and tetrahydrouridine combination not only increases exposure to decitabine but reduces exposure to unfavorable decitabine metabolites in healthy volunteers

Helene Hausner, Hanne Kjær Offenberg, Marie Aavang Geist et al. Nov 03, 2025 pp. 4737-4737 10.1182/blood-2025-4737

Abstract Background: The modified-release fixed combination of decitabine and tetrahydrouridine (THU), NDec, is an inves...

A chronotherapeutic approach to VIP receptor antagonist (ANT308) in anti-tumor activity

Isabella Lin, Shayna Jankowski, Edmund Waller Nov 03, 2025 pp. 3011-3011 10.1182/blood-2025-3011

Abstract Introduction: Heterogeneity in patient response to cancer treatment can be influenced by many factors, including the time-of-day tr...

Reduced overall survival in TP53-mutated ccus is driven by prior cytotoxic exposure and cytopenia rather than leukemic progression

Steven Tessier, Yazan Jabban, Hassan Alkhateeb et al. Nov 03, 2025 pp. 5643-5643 10.1182/blood-2025-5643

Abstract Background: TP53-mutated (TP53mut) myeloid neoplasms (MN) are a biologically and clinically distinct subgroup of blood cancers asso...

Phase 1b study of cyclophosphamide, pomalidomide, dexamethasone, and daratumumab (CPD-DARA) in relapsed/refractory multiple myeloma: Safety and efficacy in a heavily pretreated population

Janusz Krawczyk, Dawn Swan, John Quinn et al. Nov 03, 2025 pp. 4031-4031 10.1182/blood-2025-4031

Abstract Introduction Multiple myeloma (MM) is an incurable malignancy of clonal plasma cells. Incorporation of the monoclonal antibody darat...

Cytomegalovirus reactivation in teclistamab-treated multiple myeloma patients: Clinical outcomes and risk factors

Hira Cheema, Asis Shrestha, Syed Naqvi et al. Nov 03, 2025 pp. 4599-4599 10.1182/blood-2025-4599

Abstract Background: Teclistamab, a bispecific T-cell engager targeting BCMA, has demonstrated significant efficacy in relapsed/refractory m...

NPM1 and IDH1/2 mutations show limited prognostic impact in relapsed AML: Evidence from the avalon cohort

Calogero Vetro, Irene Azzali, Elisabetta Petracci et al. Nov 03, 2025 pp. 6967-6967 10.1182/blood-2025-6967

Abstract Background: NPM1 and IDH1/2 mutations are established prognostic biomarkers in newly diagnosed (ND) acute myeloid leukemia (AML) tr...

Effectiveness of remote patient monitoring in enabling outpatient step-up dosing for bispecifics at a large academic cancer center in the USA

Sridevi Rajeeve, Matt Wilkes, Nicole Zahradka et al. Nov 03, 2025 pp. 2751-2751 10.1182/blood-2025-2751

Abstract Background Teclistamab (Tec) and talquetamab (Tal) are the two first approved T-cell engaging bispecific antibodies (BsAbs) for the...

Global patterns and inequities in environmental exposure-associated leukemia mortality by sex and socio-demographic index: A 32-year global analysis

Amar Lal, Shree Rath, Hyma Polimera Nov 03, 2025 pp. 8184-8184 10.1182/blood-2025-8184

Abstract Introduction: Leukemia, a malignant neoplasm of the hematopoietic system, remains a substantial contributor to...

From 1968 to 2050: Trends and forecasts of acute lymphoblastic leukemia mortality among older adults in United States

Haseeb Tareen, Allah Dad, Usman Mazhar et al. Nov 03, 2025 pp. 5111-5111 10.1182/blood-2025-5111

Abstract Introduction: Acute lymphoblastic leukemia (ALL) remains a rare but aggressive hematologic malignancy among older adults, with limi...

Treatment options, responses and outcome of 1220 classic Hodgkin lymphoma patients included in realysa, a prospective multicentric lysa cohort

Hervé Ghesquieres, Catherine Thieblemont, Aurelien Belot et al. Nov 03, 2025 pp. 1853-1853 10.1182/blood-2025-1853

Abstract Background: Classic Hodgkin lymphoma (cHL) therapies are progressing with different first-line chemotherapy regimens (CT), possibly...

TP53 exon 7 (c.742C>T; p. Arg248Trp) vaf suppression by novel oral allosteric NEK7 inhibitor in a patient with low-risk myelodysplastic syndrome in A phase 2 clinical trial

Devan Bursey, Victoria Allgood, Andrea Groen et al. Nov 03, 2025 pp. 7379-7379 10.1182/blood-2025-7379

Abstract TP53 exon 7 (c.742C>T; p. Arg248Trp) VAF Suppression by Novel Oral Allosteric NEK7 Inhibitor in a Patient with Low-Risk Myel...

Germline variant database and visualization platform for BMF and hematologic malignancy predisposition syndromes: BMFgenes1.0

Lili Kotmayer, Andrew Willems, Jian Wang et al. Nov 03, 2025 pp. 3222-3222 10.1182/blood-2025-3222

Abstract Background: In clinical practice, interpreting novel germline variants in bone marrow failure (BMF) and hematologic malignancy (HM)...

Myelofibrosis stem cell fitness requires microenvironmental cell interactions

Min Lu, MD Babu Mia, Lijuan Xia et al. Nov 03, 2025 pp. 1981-1981 10.1182/blood-2025-1981

Abstract Myelofibrosis (MF) originates at the level of the hematopoietic stem/progenitor cell (HSPC), and is associated with profound abnorm...

Mitoxantrone liposome, subcutaneous cytarabine and G-CSF (CMG) combined with venetoclax as first-line treatment in secondary Acute Myeloid Leukemia (sAML) or elderly AML patients: A multicenter, prospective, single-arm clinical trial with concurrent control

Xiaoqian Xu, Ying Lu, Weiying Bao et al. Nov 03, 2025 pp. 3447-3447 10.1182/blood-2025-3447

Abstract Objective: The prognosis of secondary acute myeloid leukemia (sAML) including AML with antecedent myelodysplastic syndromes (MDS) o...

Risk factors and mortality associated with venous thromboembolism in elderly patients with non-Hodgkin lymphoma

Ambarina Faiz, Ashwin Sridharan, Shuang Guo et al. Nov 03, 2025 pp. 3135-3135 10.1182/blood-2025-3135

Abstract Risk factors and mortality associated with venous thromboembolism in elderly patients with non-Hodgkin lymphoma...

Mixed phenotype acute leukemia: Clinical characteristics and real-world outcomes

Ana Patiño, Hong Chang, Mark Turingan et al. Nov 03, 2025 pp. 3330-3330 10.1182/blood-2025-3330

Abstract Introduction MPAL is a rare, heterogeneous leukemia defined by myeloid and lymphoid marker co-expression. The 2022 WHO classifies su...

RNA-sequencing improves risk stratification and guides treatment decision-making in acute lymphoblastic leukemia- a UK single centre experience

Athanasia Sinti Papadaki, Robert Baker, Elisabeth Nacheva et al. Nov 03, 2025 pp. 6878-6878 10.1182/blood-2025-6878

Abstract Background: Acute lymphoblastic leukemia (ALL) is genetically heterogeneous, necessitating precise molecular characterization for o...

Early identification of thrombosis risk in adult acute lymphoblastic leukemia

Fausto Rios-Olais, Manuel Alejandro Cruz Martínez, Juan Ontiveros-Austria et al. Nov 03, 2025 pp. 5109-5109 10.1182/blood-2025-5109

Abstract Background: Thrombosis is a known complication in patients with acute lymphoblastic leukemia (ALL) that potentially impacts morbidi...

Estimation of post-transfusion HbA level is relevant after RBC exchange in sickle cell adult patients

Capucine Belcadi, Armand Mekontso Dessap, Stephane Moutereau et al. Nov 03, 2025 pp. 6503-6503 10.1182/blood-2025-6503

Abstract Background Transfusion (TF), or exchange transfusion (ExTF), is a major therapy for sickle cell disease (SCD) patients. However, th...

Chromosome genomic array testing (CGAT) improves diagnostic yield in patients with AML and MDS and has the potential for better risk stratefication - an NCI myelomatch and SWOG report

Min Fang, Megan Othus, Xiaoyu Qu et al. Nov 03, 2025 pp. 3501-3501 10.1182/blood-2025-3501

Abstract Introduction: Chromosome genomic array testing (CGAT) has been widely used in clinical genomic laboratories for...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page